Activation of peroxisome proliferator-activated receptor-γ (PPARγ) induces cell death through MAPK-dependent mechanism in osteoblastic cells

Toxicology and Applied Pharmacology

Volumn 215, Issue 2, 2006, Pages 198-207

  Kim, Sung Hun ^a   Yoo, Chong Il ^a   Kim, Hui Taek ^a   Park, Ji Yeon ^a   Kwon, Chae Hwa ^a   Keun Kim, Yong ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Cell death; Ciglitazone; MAPK; Mitochondrial dysfunction; Osteoblastic cells; PPAR

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; CASPASE; CIGLITAZONE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; SURAMIN; TROGLITAZONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; TIME;

3T3 CELLS; ANILIDES; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL SURVIVAL; CHROMANS; CLOFIBRIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES;

EID: 33746909073     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.03.001     Document Type: Article

References (64)

1. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., and Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113 (2004) 846-855
2. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., and Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146 (2005) 1226-1235
3. Antonsson B., Montessuit S., Lauper S., Eskes R., and Martinou J.C. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem. J. 345 Pt. 2 (2000) 271-278
4. Atarod E.B., and Kehrer J.P. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Free Radical Biol. Med. 37 (2004) 36-47
5. Bhat N.R., and Zhang P. Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. J. Neurochem. 72 (1999) 112-119
6. Birbes H., Bawab S.E., Obeid L.M., and Hannun Y.A. Mitochondria and ceramide: intertwined roles in regulation of apoptosis. Adv. Enzyme Regul. 42 (2002) 113-129
7. Bishop-Bailey D., and Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J. Biol. Chem. 274 (1999) 17042-17048
8. Bruemmer D., Yin F., Liu J., Berger J.P., Sakai T., Blaschke F., Fleck E., Van Herle A.J., Forman B.M., and Law R.E. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ. Res. 93 (2003) e38-e47
9. Chattopadhyay N., Singh D.P., Heese O., Godbole M.M., Sinohara T., Black P.M., and Brown E.M. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J. Neurosci. Res. 61 (2000) 67-74
10. Chen F., Wang M., O'Connor J.P., He M., Tripathi T., and Harrison L.E. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J. Cell. Biochem. 90 (2003) 732-744
11. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., and Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273 (1998) 25573-25580
12. Choi B.K., Choi C.H., Oh H.L., and Kim Y.K. Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. NeuroToxicology 25 (2004) 915-924
13. Clay C.E., Monjazeb A., Thorburn J., Chilton F.H., and High K.P. 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J. Lipid Res. 43 (2002) 1818-1828
14. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71 (1999) 479-500
15. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-16
16. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
17. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89 (1986) 271-277
18. Desagher S., and Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 10 (2000) 369-377
19. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., and Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992) 879-887
20. Gardner O.S., Dewar B.J., Earp H.S., Samet J.M., and Graves L.M. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J. Biol. Chem. 278 (2003) 46261-46269
21. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
22. Guan Y., and Breyer M.D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 60 (2001) 14-30
23. Hassouna I., Wickert H., Zimmermann M., and Gillardon F. Increase in Bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci. Lett. 204 (1996) 85-88
24. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
25. Jackson S.M., and Demer L.L. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 471 (2000) 119-124
26. Kanis J.A., Melton III L.J., Christiansen C., Johnston C.C., and Khaltaev N. The diagnosis of osteoporosis. J. Bone Miner. Res. 9 (1994) 1137-1141
27. Kim E.J., Park K.S., Chung S.Y., Sheen Y.Y., Moon D.C., Song Y.S., Kim K.S., Song S., Yun Y.P., Lee M.K., Oh K.W., Yoon do Y., and Hong J.T. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J. Pharmacol. Exp. Ther. 307 (2003) 505-517
28. Kim Y.K., Kim H.J., Kwon C.H., Kim J.H., Woo J.S., Jung J.s., and Kim J.M. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J. Appl. Toxicol. 25 (2005) 374-382
29. Kondo M., Oya-Ito T., Kumagai T., Osawa T., and Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem. 276 (2001) 12076-12083
30. Kramer D.K., Al-Khalili L., Perrini S., Skogsberg J., Wretenberg P., Kannisto K., Wallberg-Henriksson H., Ehrenborg E., Zierath J.R., and Krook A. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor {delta}. Diabetes 54 (2005) 1157-1163
31. Lee W.C., Choi C.H., Cha S.H., Oh H.L., and Kim Y.K. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem. Res. 30 (2005) 263-270
32. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., Plunket K.D., Shenk J.L., Stimmel J.B., Therapontos C., Willson T.M., and Blanchard S.G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 (2002) 6640-6650
33. Lennon A.M., Ramauge M., Dessouroux A., and Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J. Biol. Chem. 277 (2002) 29681-29685
34. Li L., Tao J., Davaille J., Feral C., Mallat A., Rieusset J., Vidal H., and Lotersztajn S. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 276 (2001) 38152-38158
35. Lim S.Y., Jang J.H., Na H.K., Lu S.C., Rahman I., and Surh Y.J. 15-Deoxy-Delta12,14-prostaglandin J(2) protects against nitrosative PC12 cell death through up-regulation of intracellular glutathione synthesis. J. Biol. Chem. 279 (2004) 46263-46270
36. Liu J.J., Huang R.W., Lin D.J., Peng J., Wu X.Y., Lin Q., Pan X.L., Song Y.Q., Zhang M.H., Hou M., and Chen F. Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann. Oncol. 16 (2005) 455-459
37. Manolagas S.C. Cellular and molecular mechanisms of osteoporosis. Aging (Milano) 10 (1998) 182-190
38. Martindale J.L., and Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192 (2002) 1-15
39. Narayanan P.K., Hart T., Elcock F., Zhang C., Hahn L., McFarland D., Schwartz L., Morgan D.G., and Bugelski P. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry A 52 (2003) 28-35
40. Nikitakis N.G., Siavash H., Hebert C., Reynolds M.A., Hamburger A.W., and Sauk J.J. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br. J. Cancer 87 (2002) 1396-1403
41. Ogawa S., Urano T., Hosoi T., Miyao M., Hoshino S., Fujita M., Shiraki M., Orimo H., Ouchi Y., and Inoue S. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem. Biophys. Res. Commun. 260 (1999) 122-126
42. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., and Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur. J. Pharmacol. 407 (2000) 227-235
43. Padilla J., Kaur K., Cao H.J., Smith T.J., and Phipps R.P. Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J. Immunol. 165 (2000) 6941-6948
44. Pastorino J.G., Chen S.T., Tafani M., Snyder J.W., and Farber J.L. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J. Biol. Chem. 273 (1998) 7770-7775
45. Perez-Ortiz J.M., Tranque P., Vaquero C.F., Domingo B., Molina F., Calvo S., Jordan J., Cena V., and Llopis J. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J. Biol. Chem. 279 (2004) 8976-8985
46. Piva R., Gianferretti P., Ciucci A., Taulli R., Belardo G., and Santoro M.G. 15-Deoxy-{Delta}12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-{kappa}B activity and down-regulation of antiapoptotic proteins. Blood 105 (2005) 1750-1758
47. Riggs B.L., and Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 (2005) 177-184
48. Rosen E.D., and Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731-37734
49. Rovin B.H., Wilmer W.A., Lu L., Doseff A.I., Dixon C., Kotur M., and Hilbelink T. 15-Deoxy-Delta12,14-prostaglandin J2 regulates mesangial cell proliferation and death. Kidney Int. 61 (2002) 1293-1302
50. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., and Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 (2004) 401-406
51. Shan Z.Z., Masuko-Hongo K., Dai S.M., Nakamura H., Kato T., and Nishioka K. A potential role of 15-deoxy-delta(12,14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J. Biol. Chem. 279 (2004) 37939-37950
52. Shen Z.N., Nishida K., Doi H., Oohashi T., Hirohata S., Ozaki T., Yoshida A., Ninomiya Y., and Inoue H. Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem. Biophys. Res. Commun. 328 (2005) 375-382
53. Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J., and Kolar Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 52 (2005) 126-136
54. Teruel T., Hernandez R., Benito M., and Lorenzo M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J. Biol. Chem. 278 (2003) 263-269
55. Tsuchiya T., Shimizu H., Shimomura K., and Mori M. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am. J. Nephrol. 23 (2003) 222-228
56. Wang Y.L., Frauwirth K.A., Rangwala S.M., Lazar M.A., and Thompson C.B. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J. Biol. Chem. 277 (2002) 31781-31788
57. Ward C., Dransfield I., Murray J., Farrow S.N., Haslett C., and Rossi A.G. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J. Immunol. 168 (2002) 6232-6243
58. Werner A.L., and Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21 (2001) 1082-1099
59. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341-367
60. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
61. Yamakawa-Karakida N., Sugita K., Inukai T., Goi K., Nakamura M., Uno K., Sato H., Kagami K., Barker N., and Nakazawa S. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ. 9 (2002) 513-526
62. Yasuda E., Tokuda H., Ishisaki A., Hirade K., Kanno Y., Hanai Y., Nakamura N., Noda T., Katagiri Y., and Kozawa O. PPAR-gamma ligands up-regulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/JNK activation in osteoblasts. Biochem. Biophys. Res. Commun. 328 (2005) 137-143
63. Yin C., Knudson C.M., Korsmeyer S.J., and Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385 (1997) 637-640
64. Zander T., Kraus J.A., Grommes C., Schlegel U., Feinstein D., Klockgether T., Landreth G., Koenigsknecht J., and Heneka M.T. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J. Neurochem. 81 (2002) 1052-1060